I joined Genentech in 2007 with 10 years of prior industry experience in the US and Germany.
I did my doctoral studies in organic chemistry at the Max-Planck Institute in Mülheim, Germany, in the group of Manfred Reetz, followed by a post-doctoral stay at The Scripps Research Institute in the laboratory of K. Barry Sharpless. My pharmaceutical industry career began in 1997 at Bayer in Germany and continued in the Bayer Pharmaceutical Research Center in West Haven, Connecticut until 2007.
ACS Med Chem Lett. 2015 May; 6(6): 711-5.
Nat Rev Drug Discov. 2014 Aug; 13(8): 588-602.
I lead multiple cross-functional project teams to discover small molecule cancer drugs. I thrive on the day-to-day interactions with chemists, biologists, toxicologists, and other scientists who are all working towards a common goal.
One of my main interests is on innovative approaches to harness small molecule binders to selectively kill cancer cells. I believe that chemists have unique skill sets and imagination to contribute to the innovation needed to tackle the non-traditional drug target space.
I have a particular interest in furthering my understanding of the effects of protein conformation induced by drug molecules and drug binding kinetics on the functional response of drugs in cells. I am convinced that a more refined grasp of the interplay of these factors will help us find more effective and safer medicines for patients.